JPMorgan Chase & Co. reduced its stake in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 11.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,511,517 shares of the company's stock after selling 194,665 shares during the quarter. JPMorgan Chase & Co. owned about 1.42% of Annexon worth $7,754,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of the stock. Prudential Financial Inc. raised its position in shares of Annexon by 6.4% during the 4th quarter. Prudential Financial Inc. now owns 171,680 shares of the company's stock valued at $881,000 after buying an additional 10,400 shares in the last quarter. Vanguard Group Inc. increased its stake in Annexon by 11.6% in the fourth quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company's stock valued at $28,456,000 after acquiring an additional 576,625 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Annexon during the fourth quarter valued at about $98,000. American Century Companies Inc. lifted its stake in Annexon by 23.8% during the fourth quarter. American Century Companies Inc. now owns 178,511 shares of the company's stock worth $916,000 after purchasing an additional 34,297 shares during the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in shares of Annexon in the 4th quarter worth about $106,000.
Annexon Stock Performance
NASDAQ:ANNX traded up $0.08 during trading hours on Tuesday, reaching $1.76. The company's stock had a trading volume of 4,233,138 shares, compared to its average volume of 1,823,832. The firm has a market capitalization of $193.09 million, a price-to-earnings ratio of -1.68 and a beta of 1.24. The firm has a 50-day simple moving average of $2.23 and a 200-day simple moving average of $4.34. Annexon, Inc. has a 1 year low of $1.29 and a 1 year high of $7.85.
Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Equities analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC reissued a "buy" rating and set a $16.00 price objective on shares of Annexon in a report on Tuesday, March 4th.
Check Out Our Latest Analysis on Annexon
Annexon Profile
(
Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Stories
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
